Table 4.

Overview of All Reported Adverse Events^a

n (%)	Tiotropium Respimat®5 μg QD(n = 98)	Tiotropium Respimat®2.5 μg BID(n = 98)
Any adverse event	18 (18.4)	19 (19.4)
Nasopharyngitis	4 (4.1)	4 (4.1)
Headache	3 (3.1)	2 (2.0)
Dysphonia	1 (1.0)	2 (2.0)
Rhinitis	1 (1.0)	2 (2.0)
Asthma worsening	2 (2.0)	0
Contusion	2 (2.0)	0
Cough	0	2 (2.0)
Dry mouth	0	2 (2.0)
Rash	1 (1.0)	1 (1.0)
Urticaria	1 (1.0)	1 (1.0)
Investigator-defined drug-related adverse events	1 (1.0)	2 (2.0)
Adverse events leading to discontinuation	0	1 (1.0)
Serious adverse events	0	1 (1.0)

Treated set.

^aFrequency of adverse events that occurred in more than one patient in any treatment group, sorted by preferred term and system organ class.

BID, twice daily; QD, once daily.